Recently, investigations into the relationship between p53 and HER2 expression, and response to neoadjuvant chemotherapy, in resected lung cancer demonstrated a tendency toward chemoresistance in tumors with a high level of HER2 expression [16]. This evidence concerns the gene ERBB2 and lung cancer.